drugset / Trial / NCT05796752

Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors

NCT05796752

Phase 2/3 Active not recruiting 26 enrolled University of Chicago
NaSingle-groupOpen-labelTreatment

Summary

The goal of the proposed study is to compare the efficacy of behavioral treatment (BT) to memantine, a psychopharmacological agent, for BFRBs. 28 subjects with trichotillomania (TTM) or skin picking disorder (SPD) will receive 8 weeks of memantine treatment, followed by 8 weeks of comprehensive behavioral therapy (ComB) treatment. The hypothesis to be tested is that behavioral therapy will be associated with superior clinical outcomes as compared to memantine. A second hypothesis is that both memantine and behavioral therapy will demonstrate improvement from baseline to the respective posttreatment assessment.

Timeline

Start
2023-08-02
Primary completion
2026-04-16
Completion
2027-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 20 mg Oral